XML 59 R49.htm IDEA: XBRL DOCUMENT v3.26.1
ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2026
May 31, 2026
Apr. 30, 2026
Jan. 31, 2025
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Asset Acquisition [Line Items]              
Acquired in-process research and development expenses           $ 12,150 $ 315
Lakefront              
Asset Acquisition [Line Items]              
Percentage share of payment of upfront cash consideration 50.00%            
Reduction to acquired in-process research and development expenses         $ 860 $ 860  
Lakefront | Minimum              
Asset Acquisition [Line Items]              
Sales based tired royalty, low-end, percentage 20.00%       20.00% 20.00%  
Lakefront | Maximum              
Asset Acquisition [Line Items]              
Sales based tired royalty, high-end, percentage 23.00%       23.00% 23.00%  
LEO Pharma A/S | LEO Pharma A/S Agreement              
Asset Acquisition [Line Items]              
Payments to acquire in process research and development       $ 250      
Additional payments (up to)       $ 1,500      
Ouro Medicines LLC              
Asset Acquisition [Line Items]              
Total consideration transferred $ 1,900            
Cash consideration 1,600            
Potential future milestone payments, maximum 500       $ 500 $ 500  
Acquired in-process research and development expenses         1,900 1,900  
Stock-based compensation expense         135 135  
Ouro Medicines LLC | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost              
Asset Acquisition [Line Items]              
Stock-based compensation expense         45 45  
Ouro Medicines LLC | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense              
Asset Acquisition [Line Items]              
Stock-based compensation expense         91 91  
Ouro Medicines LLC | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesCurrent              
Asset Acquisition [Line Items]              
Contingent liability 143       143 143  
Ouro Medicines LLC | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesNoncurrent              
Asset Acquisition [Line Items]              
Contingent liability $ 133       133 133  
Tubulis GmbH              
Asset Acquisition [Line Items]              
Total consideration transferred   $ 3,200          
Potential future milestone payments, maximum   $ 1,900          
Acquired in-process research and development expenses         3,100 3,100  
Stock-based compensation expense         51 51  
Tubulis GmbH | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost              
Asset Acquisition [Line Items]              
Stock-based compensation expense         28 28  
Tubulis GmbH | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense              
Asset Acquisition [Line Items]              
Stock-based compensation expense         23 23  
Arcellx, Inc              
Asset Acquisition [Line Items]              
Total consideration transferred     $ 6,400        
Acquired in-process research and development expenses         7,000 7,000  
Stock-based compensation expense         375 375  
Assets acquired     324        
Liabilities assumed     88        
Settled investments     $ 773        
Contingent value right (in dollars per share)     $ 5        
Contingent value right, amount     $ 300        
Contingent value right, sales threshold     $ 6,000        
Arcellx, Inc | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost              
Asset Acquisition [Line Items]              
Stock-based compensation expense         156 156  
Arcellx, Inc | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense              
Asset Acquisition [Line Items]              
Stock-based compensation expense         $ 218 $ 218